Which way protects babies best from RSV: a birth shot or a vaccine for mom?
A shot given to the baby at birth offers the most reliable protection. In this study of 164,140 infants, babies who got nirsevimab shortly after birth had about a 26 percent lower risk of being hospitalised for RSV than babies protected only by their mother’s vaccine. But timing changed the picture in an important way.
RSV stands for respiratory syncytial virus. It is a common bug that causes coughs and colds in most people. In babies, though, it can settle deep in the lungs and make breathing hard. RSV is one of the top reasons young infants end up in the hospital during their first winter. So protecting newborns from it matters a great deal.
There are now two ways to do this. The first is nirsevimab, a long-acting antibody shot given straight to the baby soon after birth. The second is RSVpreF, a vaccine given to the mother during pregnancy so she passes protection to her baby before birth. Until now, it was not clear which approach worked better in the real world.
What the data show
This was a French nationwide study that followed 164,140 infants during the 2024 to 2025 RSV season. Researchers compared the two strategies head to head by looking at who ended up in the hospital with an RSV-related lower respiratory tract infection, meaning an infection in the lungs and airways.
Babies who received nirsevimab at birth had roughly a 26 percent lower risk of RSV hospitalisation than babies protected only through their mother’s vaccine. That is a meaningful gap when you are talking about hospital stays in tiny infants. But the most useful finding was about timing. When mothers were vaccinated at least 8 weeks before giving birth, the protection their babies got was statistically about the same as the baby getting nirsevimab. In other words, the gap closed when moms were vaccinated early enough.
Dr. Kumar’s Take
What I find genuinely helpful here is that this is real-world data, not a lab result. Over 164,000 babies is a huge number, and it tells us how these tools actually perform in everyday life. My honest read is that nirsevimab at birth is the more forgiving option, because it does not depend on getting the timing right during pregnancy. It protects the baby directly, right away.
That said, the maternal vaccine is not second best, it is simply more sensitive to timing. If a mother is vaccinated at least 8 weeks before delivery, her baby appears to get protection on par with the antibody shot. The catch is that babies who arrive early, or whose mothers are vaccinated late in pregnancy, may not get the full benefit. So the lesson is less “one is better” and more “timing is the lever you can actually control.”
Who benefits most
The clearest winners from early action are babies born during or just before RSV season, when the virus is spreading. A newborn’s lungs and immune system are still developing, so they have the least defence against a serious lung infection. For families who choose the maternal vaccine route, getting it done well ahead of the due date is what carries the protection across to the baby.
This is also reassuring for parents who, for any reason, miss the maternal vaccine window. Nirsevimab given at birth offers a strong fallback that does not rely on what happened earlier in pregnancy. Either path can protect a baby. The key is making sure one of them is in place before RSV season arrives.
Limitations to keep in mind
This was a retrospective cohort study, which means researchers looked back at records of what already happened rather than randomly assigning babies to each strategy. That design is powerful for size and real-world relevance, but it cannot prove cause and effect as cleanly as a randomised trial. Families who chose one option may differ in other ways from families who chose the other.
The findings also reflect one country and one RSV season. Virus activity, healthcare access, and which product is offered can all vary from place to place and year to year. Still, the timing signal is consistent with how vaccines are known to work, which makes it a sensible thing to act on.
Practical Takeaways
- If you are pregnant and plan to use the maternal RSV vaccine, aim to get it at least 8 weeks before your due date so your baby has time to receive full protection.
- If the vaccine timing window is missed or your baby arrives early, ask your doctor about giving nirsevimab to your baby shortly after birth as a direct form of protection.
- Talk with your obstetrician or paediatrician about which RSV strategy fits your pregnancy timeline, since both can work well when used correctly.
- Plan ahead so protection is in place before RSV season, which usually runs through the colder months.
Related Studies and Research
- being physically fit lowers your risk of depression and dementia
- the shingles vaccine may cut dementia risk by a third in older adults
- shingles vaccine cuts heart attack risk nearly in half for heart disease patients
- a gentle chinese exercise lowers blood pressure as well as brisk walking
FAQs
Is nirsevimab a vaccine or something different?
Nirsevimab is not a traditional vaccine. It is a long-acting antibody, which means it gives the baby ready-made protection rather than training the baby’s own immune system to make it. This is why it works right away after the shot. A vaccine, like the RSVpreF given to mothers, prompts the body to build its own defences over time, which is why timing before birth matters so much for it.
Can a baby get both the maternal vaccine and nirsevimab?
In most cases, only one strategy is needed, and health guidance generally recommends choosing one rather than doubling up. If a mother was vaccinated well before delivery, her baby is usually considered protected and may not need the antibody shot. Decisions about combining the two should always be made with your paediatrician, who can weigh your baby’s birth timing and individual risk.
Why does the 8-week timing before delivery matter so much?
After a mother gets the RSVpreF vaccine, her body needs time to make protective antibodies and pass them across the placenta to the baby. Getting vaccinated at least 8 weeks before birth gives that process enough time to work fully. When the vaccine is given too close to delivery, or the baby arrives early, fewer antibodies may reach the baby, which can leave a gap in protection.
Bottom Line
In a large real-world study of more than 164,000 infants, giving nirsevimab to babies at birth lowered the risk of RSV hospitalisation by about 26 percent compared with relying on the mother’s vaccine alone. But the maternal vaccine essentially caught up when mothers were vaccinated at least 8 weeks before delivery. The takeaway is practical and hopeful: both tools can protect newborns from a dangerous lung infection, and timing is the factor families and doctors can plan around.
